News Release

January 6, 2023

FUJIFILM Cellular Dynamics Announces License Agreement with Novo Nordisk for the Development of iPSC-Derived Cell Therapies

MADISON, WIS., January 5, 2023 – FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC), announced today that it has entered an agreement to grant global healthcare company Novo Nordisk A/S a non-exclusive right to use FUJIFILM Cellular Dynamics’ iPSC platform for the development and commercialization of iPSC-derived cell therapies with a focus on addressing serious chronic diseases. 

Under the agreement, Novo Nordisk will have a non-exclusive license to use the iPSC cell lines for research and development purposes, and to utilize GMP-grade cell lines for clinical and commercial manufacture and commercialization of iPSC-derived cell therapies. Terms of the agreement were not disclosed.

“FUJIFILM Cellular Dynamics is a global leader in the development and manufacturing of GMP-grade iPSCs for cell therapy applications. Our goal is to drive the iPSC field forward by building strategic partnerships,” said Tomoyuki Hasegawa, chief executive officer, FUJIFILM Cellular Dynamics. “Novo Nordisk is strongly positioned to be a pioneer in delivering cell-based treatments to tackle serious chronic diseases based on iPSC-derived therapeutics.”

“Novo Nordisk has been at the forefront of cell therapy research for many years, and we have the ambition to deliver cell therapies with the potential to halt a disease or even reverse its progress for people living with serious chronic diseases,” said Jacob Sten Petersen, corporate vice president of Cell Therapy R&D, Novo Nordisk. “In order to fulfil that ambition, we need access to a variety of GMP-grade pluripotent stem cell lines, and we are very excited about this agreement with FUJIFILM Cellular Dynamics that provides us access to their state-of-the-art iPSC platform.”

Over the past few years FUJIFILM Cellular Dynamics has licensed its iPSC platform to numerous leading biotech companies including Cynata Therapeutics Limited, Sana Biotechnology, Lonza, among others.


Media Contact

Christine Jackman

  • * Please note that the contents including the product availability, specification, prices and contacts in this website are current as of the date of the press announcement and may be subject to change without prior notice.